Institut Für Klinische Krebsforschung Ikf Gmbh At Krankenhaus Nordwest

This study is testing whether adding immunotherapy drugs to a standard targeted radiation treatment helps control advanced bile duct cancer that starts in the liver. It will involve about 50 adults whose cancer cannot be removed by surgery. Patients will receive the radiation tre…

This study is testing whether combining two drugs, fedratinib and nivolumab, can help control myelofibrosis, a serious bone marrow cancer. It is for patients whose disease did not respond well enough to standard JAK inhibitor medications. The goal is to see if this combination ca…

This study is testing whether combining two drugs, atezolizumab and derazantinib, can help control advanced bile duct cancer that has a specific genetic feature called an FGFR2 fusion. It is for adults who have had at most one prior treatment. The main goal is to see how many pat…

This study is testing if adding a new targeted drug, bemarituzumab, to standard chemotherapy can help control advanced stomach or gastroesophageal cancer that has worsened after initial treatment. It is for adults whose tumors have a specific marker (FGFR2b-positive). The main go…

This early-stage study is testing the safety and feasibility of new ways to deliver an immune-boosting drug called IMP321 to people with advanced solid tumors. Researchers are trying methods like injecting the drug directly into tumors or into the abdominal cavity, and combining …

This study aims to see if the drug brigatinib works better than other similar drugs for people with a specific type of advanced lung cancer (ALK-positive NSCLC). It will involve about 118 adults who have not yet received treatment for their advanced cancer. Researchers will close…